Normal Nuchal Translucency: Definition and Follow-Up
A normal nuchal translucency (NT) measurement is defined as less than 3.0 mm or below the 99th percentile for crown-rump length at 11–14 weeks' gestation, and when normal, requires only routine second-trimester anatomic ultrasound without additional specialized follow-up. 1
Defining Normal NT Measurements
NT measurements below 2.0 mm carry the lowest risk of chromosomal anomalies (baseline prevalence 0.5%), establishing this as the optimal normal range. 2
The median NT increases physiologically from 0.7 mm at 10 weeks to 1.5–1.7 mm at 13 weeks, then decreases to approximately 1.0 mm by 15 weeks. 3, 4
An NT measurement of 3.0 mm or greater is considered abnormally elevated and warrants immediate action regardless of gestational age or serum marker results. 1
The 99th percentile threshold varies by crown-rump length, but the fixed cutoff of 3.0 mm provides a practical clinical threshold that captures high-risk cases while maintaining acceptable false-positive rates. 1
Follow-Up for Normal NT Measurements
Routine Prenatal Care
When NT is normal (< 3.0 mm), first-trimester combined screening should incorporate maternal serum markers (PAPP-A and free β-hCG) to calculate comprehensive aneuploidy risk, as NT alone detects only 70% of trisomy 21 cases. 1
Standard second-trimester anatomic survey at 18–22 weeks remains mandatory even with normal NT, as only 50% of major fetal anomalies can be detected before 14 weeks compared to 75% in the second trimester. 1
No additional Doppler studies, fetal echocardiography, or specialized imaging is indicated when NT is normal in the absence of other maternal or fetal risk factors. 1
Important Clinical Caveats
Normal NT does not eliminate the need for aneuploidy screening—it must be integrated with biochemical markers and maternal factors (age, weight, race, prior aneuploidy history) to generate accurate risk estimates. 1
NT should not be used as an isolated screening test for fetal anomalies or congenital heart disease, as it has poor sensitivity for structural malformations (< 25% detection rate for major cardiac defects in euploid fetuses). 1
Even measurements in the 2.0–2.9 mm range carry incrementally higher risk than measurements below 2.0 mm, though they remain below the clinical action threshold of 3.0 mm. 2
Quality Assurance Considerations
Sonographer performance monitoring is critical—laboratories should verify that median NT measurements fall within 0.9–1.1 multiples of the median (MoM) for each operator. 5
Significant inter- and intra-observer variability exists in NT measurements, underscoring the importance of standardized technique and ongoing quality assessment through programs like the Fetal Medicine Foundation or Nuchal Translucency Quality Review. 1
Transvaginal ultrasound may be necessary in approximately 5% of patients when transabdominal views are suboptimal (high BMI, multiple prior surgeries, transverse fetal lie), using identical measurement principles. 1